A 59-year-old man with a history of metabolic dysfunction–associated steatotic liver disease had an enlarging liver mass. Biopsy showed hepatocellular carcinoma. Management decisions were made.

Pembrolizumab, an anti–programmed death 1 (PD-1) antibody, was approved in 2021 as adjuvant treatment for patients with renal-cell carcinoma who were at an intermediate-to-high or high risk for ...